1. Home
  2. PCRX vs ESQ Comparison

PCRX vs ESQ Comparison

Compare PCRX & ESQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • ESQ
  • Stock Information
  • Founded
  • PCRX 2006
  • ESQ 2006
  • Country
  • PCRX United States
  • ESQ United States
  • Employees
  • PCRX N/A
  • ESQ N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • ESQ Commercial Banks
  • Sector
  • PCRX Health Care
  • ESQ Finance
  • Exchange
  • PCRX Nasdaq
  • ESQ Nasdaq
  • Market Cap
  • PCRX 1.2B
  • ESQ 756.3M
  • IPO Year
  • PCRX 2011
  • ESQ 2017
  • Fundamental
  • Price
  • PCRX $22.90
  • ESQ $96.29
  • Analyst Decision
  • PCRX Buy
  • ESQ Hold
  • Analyst Count
  • PCRX 8
  • ESQ 3
  • Target Price
  • PCRX $28.38
  • ESQ $99.00
  • AVG Volume (30 Days)
  • PCRX 525.8K
  • ESQ 175.5K
  • Earning Date
  • PCRX 07-29-2025
  • ESQ 07-24-2025
  • Dividend Yield
  • PCRX N/A
  • ESQ 0.73%
  • EPS Growth
  • PCRX N/A
  • ESQ 13.51
  • EPS
  • PCRX N/A
  • ESQ 5.27
  • Revenue
  • PCRX $702,772,000.00
  • ESQ $124,132,000.00
  • Revenue This Year
  • PCRX $7.92
  • ESQ N/A
  • Revenue Next Year
  • PCRX $11.02
  • ESQ $10.72
  • P/E Ratio
  • PCRX N/A
  • ESQ $18.32
  • Revenue Growth
  • PCRX 3.08
  • ESQ 14.72
  • 52 Week Low
  • PCRX $11.16
  • ESQ $49.16
  • 52 Week High
  • PCRX $27.64
  • ESQ $101.35
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 35.82
  • ESQ 56.40
  • Support Level
  • PCRX $22.82
  • ESQ $93.57
  • Resistance Level
  • PCRX $23.83
  • ESQ $101.28
  • Average True Range (ATR)
  • PCRX 0.74
  • ESQ 3.23
  • MACD
  • PCRX -0.02
  • ESQ 0.16
  • Stochastic Oscillator
  • PCRX 6.22
  • ESQ 58.99

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About ESQ Esquire Financial Holdings Inc.

Esquire Financial Holdings Inc is a financial holding company. Through its subsidiary, the company operates as a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. In addition, it operates a payment processing platform through third-party independent sales organizations.

Share on Social Networks: